Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone858-794-8889
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$151.86 million
Profitability
Miscellaneous
Employees281
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions
What is Halozyme Therapeutics' stock symbol?
Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
How were Halozyme Therapeutics' earnings last quarter?
Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.07. The biopharmaceutical company had revenue of $39.10 million for the quarter, compared to the consensus estimate of $42.94 million. Halozyme Therapeutics had a negative return on equity of 16.97% and a negative net margin of 23.53%. Halozyme Therapeutics's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) earnings per share. View Halozyme Therapeutics' Earnings History.
When is Halozyme Therapeutics' next earnings date?
What guidance has Halozyme Therapeutics issued on next quarter's earnings?
Halozyme Therapeutics issued an update on its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205-215 million, compared to the consensus revenue estimate of $204.91 million.
What price target have analysts set for HALO?
4 brokers have issued twelve-month price objectives for Halozyme Therapeutics' shares. Their predictions range from $17.00 to $27.00. On average, they expect Halozyme Therapeutics' share price to reach $20.50 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.
What is the consensus analysts' recommendation for Halozyme Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Halozyme Therapeutics.
What are Wall Street analysts saying about Halozyme Therapeutics stock?
Here are some recent quotes from research analysts about Halozyme Therapeutics stock:
- 1. According to Zacks Investment Research, "Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme's highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine. " (8/7/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019)
Has Halozyme Therapeutics been receiving favorable news coverage?
Headlines about HALO stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Halozyme Therapeutics.
Are investors shorting Halozyme Therapeutics?
Halozyme Therapeutics saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 7,517,400 shares, a drop of 5.5% from the June 30th total of 7,955,700 shares. Based on an average trading volume of 886,400 shares, the days-to-cover ratio is currently 8.5 days. Approximately 5.8% of the shares of the stock are short sold. View Halozyme Therapeutics' Current Options Chain.
Who are some of Halozyme Therapeutics' key competitors?
Some companies that are related to Halozyme Therapeutics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Repligen (RGEN), argenx (ARGX), Moderna (MRNA), China Biologic Products (CBPO), Ablynx (ABLYF), Spark Therapeutics (ONCE), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP) and Acceleron Pharma (XLRN).
What other stocks do shareholders of Halozyme Therapeutics own?
Who are Halozyme Therapeutics' key executives?
Halozyme Therapeutics' management team includes the folowing people:
- Dr. Helen I. Torley, Pres, CEO & Director (Age 56)
- Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)
- Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)
- Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)
- Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44)
Who are Halozyme Therapeutics' major shareholders?
Halozyme Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.09%), BlackRock Inc. (8.63%), Third Security LLC (7.36%), Invesco Ltd. (3.68%), Iridian Asset Management LLC CT (3.33%) and Pictet Asset Management Ltd. (2.54%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics.
Which institutional investors are selling Halozyme Therapeutics stock?
HALO stock was sold by a variety of institutional investors in the last quarter, including Third Security LLC, Iridian Asset Management LLC CT, First Light Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., Pictet Asset Management Ltd., Man Group plc and Granite Investment Partners LLC. Company insiders that have sold Halozyme Therapeutics company stock in the last year include Dimitrios Chondros and Randal J Kirk. View Insider Buying and Selling for Halozyme Therapeutics.
Which institutional investors are buying Halozyme Therapeutics stock?
HALO stock was purchased by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Nuveen Asset Management LLC, Point72 Asset Management L.P., Invesco Ltd., BlackRock Inc., Wells Fargo & Company MN, Marshall Wace LLP and Sofinnova Investments Inc.. View Insider Buying and Selling for Halozyme Therapeutics.
How do I buy shares of Halozyme Therapeutics?
Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Halozyme Therapeutics' stock price today?
One share of HALO stock can currently be purchased for approximately $16.28.
How big of a company is Halozyme Therapeutics?
Halozyme Therapeutics has a market capitalization of $2.38 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.
What is Halozyme Therapeutics' official website?
How can I contact Halozyme Therapeutics?
Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]
MarketBeat Community Rating for Halozyme Therapeutics (NASDAQ HALO)
MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.
